Connect with us

Technology

Study finds new dual benefit mode of action for drug candidate to fight Covid

Published

on

CmaTrends

According to the study, published in the journal Cellular and Molecular Life Sciences, this could constitute the basis for a broadly effective drug to fight Covid-19.

The drug can not only inhibit the proliferation of SARS-CoV-2 viruses in cells, but also reduce the exaggerated immune response which represents a serious problem in severe cases of Covid-19.

“In the results, we have published, we have been able for the first time to show such a dual action for an anti-Covid 19 agent,” said researcher Stephan Ludwig from the University of Munster.

The active agent in question, called Zapnometinib or ATR-002, which was originally under development as anti-flu medication, was effective in a variety of cell culture models — including activity against all tested variants of SARS-CoV-2, which also implies broad applicability in facing up to any coming variants in the future.

Animal testing to confirm these findings are currently under-way, the team said.

“Positive results from the still ongoing clinical study in humans might already lead to an emergency approval this year for a new, broadly effective Covid-19 medication. The benefit is clear,” said Ludwig.

Disclaimer: This story is auto-aggregated by a computer program and has not been created or edited by CmaTrends.Publisher : CmaTrends Media